Literature DB >> 22690067

Motor vehicle accidents: how should cirrhotic patients be managed?

Takumi Kawaguchi1, Eitaro Taniguchi, Michio Sata.   

Abstract

Motor vehicle accidents (MVAs) are serious social issues worldwide and driver illness is an important cause of MVAs. Minimal hepatic encephalopathy (MHE) is a complex cognitive dysfunction with attention deficit, which frequently occurs in cirrhotic patients independent of severity of liver disease. Although MHE is known as a risk factor for MVAs, the impact of diagnosis and treatment of MHE on MVA-related societal costs is largely unknown. Recently, Bajaj et al demonstrated valuable findings that the diagnosis of MHE by rapid screening using the inhibitory control test (ICT), and subsequent treatment with lactulose could substantially reduce the societal costs by preventing MVAs. Besides the ICT and lactulose, there are various diagnostic tools and therapeutic strategies for MHE. In this commentary, we discussed a current issue of diagnostic tools for MHE, including neuropsychological tests. We also discussed the advantages of the other therapeutic strategies for MHE, such as intake of a regular breakfast and coffee, and supplementation with zinc and branched chain amino acids, on the MVA-related societal costs.

Entities:  

Keywords:  Branched chain amino acids; Coffee; Subclinical hepatic encephalopathy; Traffic accident; Zinc

Mesh:

Substances:

Year:  2012        PMID: 22690067      PMCID: PMC3369995          DOI: 10.3748/wjg.v18.i21.2597

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  28 in total

Review 1.  Minimal hepatic encephalopathy: consensus statement of a working party of the Indian National Association for Study of the Liver.

Authors:  Radha K Dhiman; Vivek A Saraswat; Barjesh K Sharma; Shiv K Sarin; Yogesh K Chawla; Roger Butterworth; Ajay Duseja; Rakesh Aggarwal; Deepak Amarapurkar; Praveen Sharma; Kaushal Madan; Samir Shah; Avnish K Seth; Rakesh K Gupta; Abraham Koshy; Ramesh R Rai; Jang B Dilawari; Sri Prakash Mishra; Subrat K Acharya
Journal:  J Gastroenterol Hepatol       Date:  2010-06       Impact factor: 4.029

2.  Minimal hepatic encephalopathy: a vehicle for accidents and traffic violations.

Authors:  Jasmohan S Bajaj; Muhammad Hafeezullah; Raymond G Hoffmann; Kia Saeian
Journal:  Am J Gastroenterol       Date:  2007-07-19       Impact factor: 10.864

3.  Inhibitory control test for the diagnosis of minimal hepatic encephalopathy.

Authors:  Jasmohan S Bajaj; Muhammad Hafeezullah; Jose Franco; Rajiv R Varma; Raymond G Hoffmann; Joshua F Knox; Darrell Hischke; Thomas A Hammeke; Steven D Pinkerton; Kia Saeian
Journal:  Gastroenterology       Date:  2008-07-22       Impact factor: 22.682

4.  Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy.

Authors:  Y Horsmans; P M Solbreux; C Daenens; J P Desager; A P Geubel
Journal:  Aliment Pharmacol Ther       Date:  1997-02       Impact factor: 8.171

5.  Value of the apparent diffusion coefficient for quantification of low-grade hepatic encephalopathy.

Authors:  Ryosuke Sugimoto; Motoh Iwasa; Masayuki Maeda; Naohito Urawa; Hideaki Tanaka; Naoki Fujita; Yoshinao Kobayashi; Kan Takeda; Masahiko Kaito; Yoshiyuki Takei
Journal:  Am J Gastroenterol       Date:  2008-05-28       Impact factor: 10.864

6.  Treatment of chronic portal-systemic encephalopathy with lactulose.

Authors:  J Bircher; J Müller; P Guggenheim; U P Haemmerli
Journal:  Lancet       Date:  1966-04-23       Impact factor: 79.321

7.  Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis.

Authors:  Jasmohan S Bajaj; Steven D Pinkerton; Arun J Sanyal; Douglas M Heuman
Journal:  Hepatology       Date:  2012-04       Impact factor: 17.425

8.  Does coffee enriched with chlorogenic acids improve mood and cognition after acute administration in healthy elderly? A pilot study.

Authors:  Vanessa Cropley; Rodney Croft; Beata Silber; Chris Neale; Andrew Scholey; Con Stough; Jeroen Schmitt
Journal:  Psychopharmacology (Berl)       Date:  2011-07-20       Impact factor: 4.530

9.  Development of quantitative neuropsychological tests for diagnosis of subclinical hepatic encephalopathy in liver cirrhosis patients and establishment of diagnostic criteria-multicenter collaborative study in Japanese.

Authors:  Akinobu Kato; Motoichiro Kato; Hiromasa Ishii; Yosuke Ichimiya; Kazuyuki Suzuki; Hironaka Kawasaki; Shin-Ichiro Yamamoto; Ryukichi Kumashiro; Kyosuke Yamamoto; Naohiro Kawamura; Naoaki Hayashi; Shohei Matsuzaki; Akira Terano; Kiwamu Okita; Akiharu Watanabe
Journal:  Hepatol Res       Date:  2004-10       Impact factor: 4.288

Review 10.  Validating psychiatric endophenotypes: inhibitory control and attention deficit hyperactivity disorder.

Authors:  Jennifer Crosbie; Daniel Pérusse; Cathy L Barr; Russell J Schachar
Journal:  Neurosci Biobehav Rev       Date:  2007-05-18       Impact factor: 8.989

View more
  3 in total

1.  An association between dietary habits and traffic accidents in patients with chronic liver disease: A data-mining analysis.

Authors:  Takumi Kawaguchi; Takuro Suetsugu; Shyou Ogata; Minami Imanaga; Kumiko Ishii; Nao Esaki; Masako Sugimoto; Jyuri Otsuyama; Ayu Nagamatsu; Eitaro Taniguchi; Minoru Itou; Tetsuharu Oriishi; Shoko Iwasaki; Hiroko Miura; Takuji Torimura
Journal:  Biomed Rep       Date:  2016-03-23

2.  Screening for minimal hepatic encephalopathy in patients with cirrhosis by cirrhosis-related symptoms and a history of overt hepatic encephalopathy.

Authors:  Emi Yoshimura; Tatsuki Ichikawa; Hisamitsu Miyaaki; Naota Taura; Satoshi Miuma; Hidataka Shibata; Takuya Honda; Fuminao Takeshima; Kazuhiko Nakao
Journal:  Biomed Rep       Date:  2016-06-13

3.  Effect of different treatments and alcohol addiction on gut microbiota in minimal hepatic encephalopathy patients.

Authors:  Zan Zuo; Hong Fan; Xiao-Dan Tang; Yan-Min Chen; Lin-Ting Xun; Yan Li; Zheng-Ji Song; Hui-Qiong Zhai
Journal:  Exp Ther Med       Date:  2017-09-19       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.